An agent that activates natural killer cells and is useful in renal cell carcinoma is :
**Core Concept:**
Natural killer (NK) cells are a type of white blood cell that plays a crucial role in the immune system, particularly in recognizing and eliminating virus-infected cells and tumor cells. Renal cell carcinoma (RCC) is the most common type of kidney cancer. Immunotherapy is a type of treatment that boosts the body's immune system to fight cancer cells.
**Why the Correct Answer is Right:**
The correct answer, **Option C: Interferon-alpha (IFN-alpha)**, is chosen because it is a cytokine (a protein) that activates NK cells and has been proven effective in treating renal cell carcinoma. Interferons are produced by the body in response to viral infections or cancer, and they help regulate the immune response. IFN-alpha belongs to the interferon family and works by enhancing NK cell activity, leading to the destruction of cancerous cells.
**Why Each Wrong Option is Incorrect:**
Option A: **Interleukin-2 (IL-2)** is a cytokine that also activates NK cells, but it is less specific than IFN-alpha and has more severe side effects. IL-2 is primarily used for the treatment of certain types of cancer, including RCC, but IFN-alpha is more commonly used for RCC treatment due to its lower toxicity.
Option B: **Cytosine arabinoside (Ara-C)** is an antineoplastic agent (chemotherapy drug) used in the treatment of leukemia and lymphoma, not RCC. It does not activate NK cells or have any direct impact on RCC.
Option D: **Cisplatin** is a chemotherapeutic agent primarily used for the treatment of testicular cancer, ovarian cancer, and lung cancer, among others. It does not specifically activate NK cells nor target RCC.
**Clinical Pearl:**
Interferons, including IFN-alpha, are considered first-line therapy for advanced renal cell carcinoma. They work by enhancing NK cell activity, leading to the destruction of cancerous cells. However, they may cause various side effects, such as flu-like symptoms, fatigue, and low blood cell counts. The choice between IFN-alpha and IL-2 depends on the specific patient characteristics and tumor burden.
**Correct Answer Explanation:**
Interferon-alpha (IFN-alpha) is the correct answer because it is a cytokine that specifically activates NK cells, leading to the destruction of cancerous cells, particularly in renal cell carcinoma. IFN-alpha has been shown to be effective in treating advanced RCC, with fewer side effects than IL-2.